CKDXF Opthea Ltd (PK)

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of September, 2024

Commission File No. 001-39621

 

OPTHEA LIMITED

(Translation of registrant’s name into English)

 

Level 4

650 Chapel Street

South Yarra, Victoria, 3141

Australia

(Address of registrant’s principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

 

 

 

 

 

---

EXHIBIT INDEX

 

Exhibit		Description
99.1		Press Release: Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference

 

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

 

	OPTHEA LIMITED
	(Registrant)
	By:	/s/ Frederic Guerard
	Name:	Frederic Guerard
	Title:	Chief Executive Officer

 

Date: 09/03/2024

---

 

ASX, Nasdaq and Media Release

 

3rd September, 2024

 

Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference

 

Melbourne, Australia, and Princeton, NJ, US, September 3, 2024 -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present and participate in one-on-one investor meetings at the following two investor conferences in September 2024:

H.C. Wainwright 26th Annual Global Investment Conference

Presentation: Monday, September 9, 2024, 7:00 AM ET

Presenter: Frederic Guerard, PharmD, CEO

The webcast will be accessible via the link:
https://journey.ct.events/view/19df556a-f376-4c6d-af5b-d8220d561640

Cantor 2024 Global Healthcare Conference

Presentation: Thursday, September 17, 2024, 8:35 AM ET

Presenter: Frederic Guerard, PharmD, CEO

The webcast will be accessible via the link: https://wsw.com/webcast/cantor22/register.aspx?conf=cantor22&page=opt&url=https://wsw.com/webcast/cantor22/opt/1938033,

The webcasts of both presentations can also be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website, www.opthea.com.

 

 

 

 

About Opthea

 

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents.

---

To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.

 

Authorized for release to ASX by Fred Guerard, PharmD, CEO, Opthea

 

Investor Inquiries	Join our email database to receive program updates:
PJ Kelleher LifeSci Advisors LLC Email: pkelleher@lifesciadvisors.com Phone: 617-430 7579   Media Inquiries Silvana Guerci-Lena NorthStream Global Partners silvana@nsgpllc.com	Tel: +61 (0) 3 9826 0399 Email: info@opthea.com Web: www.opthea.com             Source: Opthea Limited

 

---

---